Send to

Choose Destination
Cancer Discov. 2018 Jan;8(1):OF4. doi: 10.1158/2159-8290.CD-NB2017-164. Epub 2017 Nov 21.

Poziotinib Shows Promise for Rare Lung Cancer.

[No authors listed]


Poziotinib, an EGFR inhibitor that was previously shelved as ineffective against non-small cell lung cancer, is showing promising activity in a subset of patients with EGFR exon 20 insertions. According to preliminary data from a phase II trial, the drug led to a 73% overall response rate in patients with this disease subtype, which is typically highly resistant to standard therapy.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center